News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioSpecifics Technologies Corporation (BSTC) to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013


5/3/2013 7:40:54 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LYNBROOK, N.Y., May 3, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Friday, May 10, 2013 to report its first quarter 2013 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=93618.

A replay of the call will be available one hour after the end of the conference on May 10, 2013 until 9:00 a.m. EDT on May 27, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10028021. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration (FDA) has accepted Auxilium's supplemental Biologics License Application (sBLA) for filing for XIAFLEX for the potential treatment of Peyronie's disease. The FDA is expected to take action on the application by September 6, 2013, and, if approved, XIAFLEX will be the first and only biologic treatment indicated for Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite. Auxilium has reported positive top-line data from a Phase IIa frozen shoulder study and expects to initiate the next phase trial in the second half of 2013. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human and canine lipomas, which are both in Phase II clinical trials, with top-line data from both trials expected in the second half of 2013. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES